Team:UCL/Practice/Report

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <head> <script type="text/javascript" src="http://2013.igem.org/Team:UCL/static/head.js?action=raw&ctype=text/javascript"> </script> <link rel="stylesheet" type="text...")
 
(12 intermediate revisions not shown)
Line 11: Line 11:
<script>
<script>
-
var word1 = "ESSAY";
+
var word1 = "FEAS";
-
var word2 = "PAGE";
+
var word2 = "ABILITY";
</script>
</script>
Line 46: Line 46:
<div class="full_page">
<div class="full_page">
-
<div class="main_image"></div>
+
<div class="main_image" style="background-image:url('http://2013.igem.org/wiki/images/f/f3/Twobrain.png');">
-
<p class="major_title">MAJOR TITLE</p>
+
</div>
-
<p class="minor_title">Minor Title</p>
+
 
 +
<div class="gap">
 +
</div>
 +
 
 +
<p class="major_title">FEASIBILITY REPORT</p>
 +
<p class="minor_title">A Practical Assessment Of Implementing Our Treatment</p>
<p class="body_text">
<p class="body_text">
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus vel fringilla diam. Integer placerat sapien sed risus mollis, eget hendrerit lorem tincidunt. Cras a sem eros. Ut nec ligula eget tortor ornare tempus sit amet quis risus. Quisque condimentum, ipsum ac rhoncus ornare, tellus augue imperdiet libero, in venenatis justo arcu quis tellus. Vivamus magna libero, tempus ac augue at, placerat vulputate nunc. Praesent fringilla id erat ut sagittis. Sed nec semper risus, nec condimentum leo. Vestibulum pharetra pellentesque augue, non ultrices leo varius et. Vestibulum id egestas orci. Vestibulum metus ipsum, iaculis nec sapien in, fringilla cursus orci. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur eget vulputate ligula. Sed venenatis nulla et porta pharetra. Suspendisse pharetra suscipit justo sagittis consequat. Morbi eu iaculis diam, ac rhoncus urna. Pellentesque eros ligula, mollis vitae metus sit amet, interdum gravida nunc. Duis tempor quam id rhoncus sodales. Nunc commodo accumsan orci ut faucibus. Quisque vitae luctus libero. Nullam risus libero, convallis et viverra sit amet, convallis a neque. Integer adipiscing ac arcu sit amet luctus. In dignissim mauris non justo tempor, in rhoncus augue volutpat. Duis euismod sodales blandit. Vivamus volutpat molestie dignissim. Quisque cursus quam cursus dui faucibus convallis. Praesent dignissim, sem ut posuere accumsan, libero diam consequat libero, vel tempor dui mi sed massa. Aenean eros arcu, sollicitudin a euismod eu, placerat vel nunc. Nunc consequat blandit fermentum. Curabitur ante erat, lobortis ac faucibus a, sollicitudin egestas nisi. Morbi ut dolor scelerisque, fermentum est vitae, commodo tortor. Vestibulum ornare semper lorem vel volutpat. In erat ligula, auctor eu pellentesque vitae, sollicitudin id sapien. Duis pharetra sagittis purus hendrerit pharetra. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus elementum iaculis neque nec fringilla. Nunc a scelerisque nulla, et varius massa. In eu pretium eros. Quisque nec lacus elit. Mauris malesuada luctus dapibus. Vivamus eget ultricies sem. Quisque nulla tellus, euismod vel vehicula adipiscing, ornare sit amet dui. Sed eget mauris aliquam, feugiat diam vel, lacinia nunc. Ut vel est facilisis, dictum sem sit amet, lobortis arcu. In hac habitasse platea dictumst. Fusce ut accumsan sapien. Sed pharetra ullamcorper dolor vitae rutrum. Aliquam luctus mattis felis vitae semper. Vivamus id sodales purus. Cras quis quam non tortor tincidunt laoreet varius suscipit lectus. Curabitur faucibus et libero quis vulputate. Nunc sed gravida libero. Phasellus eleifend, metus mattis molestie luctus, augue libero lacinia massa, ac volutpat tortor tortor quis sapien. Donec ultrices felis ut arcu rutrum sollicitudin. Praesent nec ligula at risus hendrerit aliquam. Etiam vestibulum aliquam ultricies. Ut semper libero volutpat, rutrum enim et, eleifend nibh. Nulla ornare, elit sed laoreet condimentum, quam nunc auctor sem, eu commodo elit ante id magna.  
+
We conducted a feasibility report on how likely it is that our remedy would be accepted by the public and government, and the competitiveness of our remedy, in light of recent <a href="http://www.reuters.com/article/2013/05/07/us-baxter-study-alzheimers-idUSBRE9460E020130507" target="_blank">pharmaceutical failures </a> for <a href="http://2013.igem.org/Team:UCL/Background/Alzheimers" target="_blank">Alzheimer’s Disease (AD)</a>.
</p>
</p>
 +
 +
<p class="body_text">
 +
It is clear that a cure for AD is <a href="http://www.alzheimers.org.uk/infographic" target="_blank">desperately sought</a> after. Using the result of <a href="http://2013.igem.org/Team:UCL/Practice/Survey" target="_blank">surveys</a> and discussions with medical doctors and carers of patients with AD we concluded that even with the <a href="http://www.utwente.nl/gw/wijsb/organization/brey/Publicaties_Brey/Brey_2009_Biomed_Engineering.pdf" target="_blank">controversy</a> of synthetic biology, if a safe and effective treatment were created, patients, carers, relatives, members of the public would all support our treatment.
 +
</p>
 +
 +
<p class="body_text">
 +
Also, we made estimates towards the costs of our proposed treatment and the issues our product has to overcome to be marketable. A high price would mean less people would be able to afford it, however, it is necessary as most innovative technologies start out at a high price but becomes more affordable with time. Furthermore, even at the high price, people would still want to use our treatment (given that it’s proven successful), because no drugs have been deemed cost-effective so far.
 +
</p>
 +
 +
<p class="minor_title">The Report</p>
 +
<p class="body_text">
 +
In this report, team member <a href="http://2013.igem.org/Team:UCL/Team/Profile" target="_blank">Andy Cheng</a> examines the economic feasibility of distributing  our proposed treatment, looking at resource allocation, the cost of research for AD and the <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526383/" target="_blank">cost-benefit</a> of spending on the ageing population.
 +
</p>
 +
 +
<div class="gap"></div>
<div class="gap"></div>
 +
 +
<p class="body_text"><b> <a href="http://2013.igem.org/Team:UCL/Practice/treatmentfeasibility" target="_blank">Feasibility Report: GEM Cell Treatment</a></p>
 +
 +
 +
 +
<div class="gap"></div>
 +
<!-- END CONTENT ------------------------------------------------------------------------------------------------------>
<!-- END CONTENT ------------------------------------------------------------------------------------------------------>

Latest revision as of 01:15, 5 October 2013

FEASIBILITY REPORT

A Practical Assessment Of Implementing Our Treatment

We conducted a feasibility report on how likely it is that our remedy would be accepted by the public and government, and the competitiveness of our remedy, in light of recent pharmaceutical failures for Alzheimer’s Disease (AD).

It is clear that a cure for AD is desperately sought after. Using the result of surveys and discussions with medical doctors and carers of patients with AD we concluded that even with the controversy of synthetic biology, if a safe and effective treatment were created, patients, carers, relatives, members of the public would all support our treatment.

Also, we made estimates towards the costs of our proposed treatment and the issues our product has to overcome to be marketable. A high price would mean less people would be able to afford it, however, it is necessary as most innovative technologies start out at a high price but becomes more affordable with time. Furthermore, even at the high price, people would still want to use our treatment (given that it’s proven successful), because no drugs have been deemed cost-effective so far.

The Report

In this report, team member Andy Cheng examines the economic feasibility of distributing our proposed treatment, looking at resource allocation, the cost of research for AD and the cost-benefit of spending on the ageing population.

Feasibility Report: GEM Cell Treatment